Fundraising Fox
Calcimedica
NASDAQ: CALCLa Jolla, US · Founded 2011 · 7 known investors
Find your way into Calcimedica
Each arrow is one introduction. Sign up to fill in the first one.
Ask Froimson Mark to introduce you to Sudarshan Hebbar
You →Froimson · together at Tulane University School of Medicine →Sudarshan
Sign up to find every way you can get introduced to Calcimedica
- Your email: who you already know at Calcimedica, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Calcimedica team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.
Founders & leadership
Calcimedica was founded in 2011 by Kenneth A. Stauderman and Gonul Velicelebi.
Board
Investors · 7
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: MESA VERDE VENTURE PARTNERS's portfolio page · Not right? Tell us
How we know: Revelation Partners's portfolio page · Not right? Tell us
How we know: Sanderling Ventures's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$142.7M disclosed across 6 rounds · 2014–2023
▶$9.1MraisedApr 2023 · 55 investors · BiotechnologyRule 506(b)
- Eric W. RobertsExecutive Officer, Director
- Daniel GeffkenExecutive Officer
- A. Rachel LehenyExecutive Officer, Director
- Kenneth A. StaudermanExecutive Officer
- Sudarshan HebbarExecutive Officer
- Eric BjerkholtDirector
- Frederic GuerardDirector
- Robert N. WilsonDirector
- Fred MiddletonDirector
- Michael J. DunnExecutive Officer
- Allan ShawDirector
- Offering amount
- $9.1M
- Amount sold
- $9.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55MraisedAug 2019 · 8 investors · PharmaceuticalsRule 506(b)
- Gerald Cagle, Ph.D.Director
- Chau KhuongDirector
- Emmett Cunningham, M.D., Ph.D.Director
- Christy Shaffer, Ph.D.Director
- Cameron Wheeler, Ph.D.Director
- Hansoo Michael KeyoungDirector
- Pamela WapnickExecutive Officer, Promoter
- Frederic GuerardExecutive Officer, Director, Promoter
- Offering amount
- $80M
- Amount sold
- $55M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$75.4MraisedJun 2018 · 16 investors · BiotechnologyRule 506(b)
- Gerald CagleDirector
- Chau KhoungDirector
- Christy ShafferDirector
- Cameron WheelerDirector
- Emmett CunninghamDirector
- Justin HanesDirector
- Jeffrey ClelandExecutive Officer, Director
- Offering amount
- $80.4M
- Amount sold
- $75.4M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedDec 2015 · 1 investors · BiotechnologyRule 506(b)
- Gerald CagleDirector
- Christy ShafferExecutive Officer, Director
- Jeffrey ClelandExecutive Officer, Director
- Justin HanesDirector
- Offering amount
- $1M
- Amount sold
- $750K
- Proceeds to insiders
- $35K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1.7MraisedMar 2015 · 2 investors · BiotechnologyRule 506(b)
- Michael O'RourkeExecutive Officer, Director
- Justin HanesDirector
- Gerald CagleDirector
- Jeffrey ClelandDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Minimum investment
- $240K
- Proceeds to insiders
- $100K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$750KraisedOct 2014 · 3 investors · BiotechnologyRule 506(b)
- JEFFREY CLELANDDirector
- GERALD CAGLEDirector
- MICHAEL O'ROURKEExecutive Officer, Director
- JUSTIN HANESExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $750K
- First sale
- Aug 2014
- Incorporated
- Limited Liability Company, Maryland, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Calcimedica do?
- CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.
- Who founded Calcimedica?
- Calcimedica was founded by Kenneth A. Stauderman, Gonul Velicelebi in 2011.
- Who are Calcimedica's investors?
- Calcimedica's investors include Aisling Capital, MESA VERDE VENTURE PARTNERS, Revelation Partners, Sanderling Ventures, Clarus Lifesciences, Clarus Ventures, OrbiMed.
- How much funding has Calcimedica raised?
- Calcimedica has disclosed $142.7M raised across 6 rounds.
- Where is Calcimedica headquartered?
- Calcimedica is headquartered in La Jolla, US.